vasopressin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vasopressin analogues	2810	113-79-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vasopressin 8-L-arginine vasopressin synthetic vasopressin 8-L-Arginine-vasopressin argipressin vasopressin tannate vasopressin injection antidiuretic hormone pitressin tannate	Molecular weight: 1084.24 Formula: C46H65N15O12S2 CLOGP: -2.31 LIPINSKI: 3 HAC: 27 HDO: 15 TPSA: 461.43 ALOGS: -3.93 ROTB: 19 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vasopressin
8-L-arginine vasopressin
synthetic vasopressin
8-L-Arginine-vasopressin
argipressin
vasopressin tannate
vasopressin injection
antidiuretic hormone
pitressin tannate

Molecular weight: 1084.24
Formula: C46H65N15O12S2
CLOGP: -2.31
LIPINSKI: 3
HAC: 27
HDO: 15
TPSA: 461.43
ALOGS: -3.93
ROTB: 19

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
40	U	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI

Approvals:

Date	Agency	Company	Orphan
None	FDA	PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	228.51	39.35	323	4272	1044442	62439985
Metabolic acidosis	170.29	39.35	77	4518	44992	63439435
Hypotension	141.94	39.35	133	4462	272471	63211956
Intentional overdose	139.41	39.35	79	4516	74073	63410354
Cardiac arrest	123.22	39.35	79	4516	92466	63391961
Shock	121.08	39.35	50	4545	23413	63461014
Multiple organ dysfunction syndrome	105.34	39.35	60	4535	56692	63427735
Acute kidney injury	99.24	39.35	108	4487	263307	63221120
Cardiogenic shock	98.59	39.35	40	4555	17892	63466535
Lactic acidosis	97.66	39.35	50	4545	38237	63446190
Septic shock	93.90	39.35	59	4536	66570	63417857
Pulseless electrical activity	82.96	39.35	28	4567	7493	63476934
Toxicity to various agents	77.13	39.35	92	4503	247158	63237269
Acute respiratory distress syndrome	72.62	39.35	35	4560	23499	63460928
Peripheral ischaemia	69.31	39.35	22	4573	4856	63479571
Bradycardia	63.27	39.35	48	4547	73179	63411248
Local anaesthetic systemic toxicity	61.29	39.35	14	4581	885	63483542
Disseminated intravascular coagulation	57.76	39.35	28	4567	19023	63465404
Coagulopathy	52.84	39.35	27	4568	20517	63463910
Circulatory collapse	51.16	39.35	27	4568	21911	63462516
Hypothermia	50.55	39.35	23	4572	13558	63470869
Respiratory failure	49.48	39.35	48	4547	101810	63382617
Diabetes insipidus	46.41	39.35	14	4581	2611	63481816
Electrocardiogram QRS complex prolonged	45.98	39.35	17	4578	5921	63478506
Dry gangrene	43.50	39.35	10	4585	650	63483777
Vasoplegia syndrome	43.11	39.35	12	4583	1687	63482740
Pulmonary oedema	43.08	39.35	34	4561	54839	63429588
Vitamin B1 decreased	42.07	39.35	8	4587	204	63484223
Haemodynamic instability	42.07	39.35	18	4577	9172	63475255
Fatigue	39.95	39.35	8	4587	888020	62596407

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	468.24	37.09	141	7647	8460	34940683
Cardiogenic shock	438.78	37.09	179	7609	26439	34922704
Multiple organ dysfunction syndrome	406.85	37.09	237	7551	76329	34872814
Appendicitis	393.01	37.09	141	7647	14666	34934477
Stress	354.52	37.09	160	7628	30187	34918956
Drug ineffective	267.95	37.09	409	7379	456342	34492801
Ascites	256.95	37.09	148	7640	46423	34902720
Ventricular fibrillation	236.45	37.09	111	7677	22843	34926300
Abdominal distension	228.28	37.09	149	7639	58343	34890800
Hyponatraemia	190.47	37.09	153	7635	82538	34866605
Sepsis	187.79	37.09	207	7581	166354	34782789
Blood phosphorus increased	184.05	37.09	68	7720	7653	34941490
Diabetes insipidus	154.83	37.09	47	7741	2881	34946262
General physical health deterioration	148.80	37.09	162	7626	128107	34821036
Constipation	110.77	37.09	144	7644	136838	34812305
Abdominal pain	109.65	37.09	157	7631	163461	34785682
Myasthenia gravis	91.77	37.09	40	7748	6900	34942243
Dry mouth	87.17	37.09	64	7724	30101	34919042
Vasoplegia syndrome	78.00	37.09	25	7763	1831	34947312
Blood uric acid increased	76.36	37.09	39	7749	9585	34939558
Off label use	72.72	37.09	231	7557	419293	34529850
Vomiting	65.18	37.09	159	7629	247462	34701681
Diarrhoea	62.65	37.09	7	7781	389905	34559238
Condition aggravated	62.23	37.09	134	7654	192062	34757081
Fatigue	53.98	37.09	9	7779	370644	34578499
Hyperphosphataemia	53.57	37.09	24	7764	4413	34944730
Renal injury	49.67	37.09	31	7757	11164	34937979
Intestinal ischaemia	48.87	37.09	27	7761	7767	34941376
Metabolic acidosis	48.39	37.09	54	7734	43626	34905517
Blood cholesterol increased	47.08	37.09	38	7750	20505	34928638
Cardiac arrest	45.73	37.09	79	7709	96080	34853063
Pulse absent	44.53	37.09	23	7765	5780	34943363
Analgesic therapy	44.23	37.09	14	7774	984	34948159
Incorrect route of product administration	43.99	37.09	32	7756	14813	34934330
Lactic acidosis	43.78	37.09	46	7742	34726	34914417
Drug ineffective for unapproved indication	40.36	37.09	37	7751	23678	34925465
Hypotension	39.91	37.09	124	7664	221525	34727618
Sleep disorder therapy	39.81	37.09	13	7775	1010	34948133
Serotonin syndrome	39.71	37.09	34	7754	19899	34929244
Dizziness	37.46	37.09	3	7785	218518	34730625

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiogenic shock	542.24	28.84	214	12139	41700	79690335
Appendicolith	514.58	28.84	140	12213	8411	79723624
Multiple organ dysfunction syndrome	497.54	28.84	279	12074	119967	79612068
Drug ineffective	468.81	28.84	692	11661	1080221	78651814
Appendicitis	392.05	28.84	140	12213	20654	79711381
Ventricular fibrillation	268.16	28.84	120	12233	31806	79700229
Stress	265.87	28.84	161	12192	79451	79652584
Ascites	252.79	28.84	153	12200	75409	79656626
Sepsis	224.93	28.84	241	12112	269187	79462848
Diabetes insipidus	199.17	28.84	60	12293	5177	79726858
Blood phosphorus increased	188.63	28.84	68	12285	10279	79721756
Abdominal distension	184.99	28.84	151	12202	119499	79612536
Metabolic acidosis	182.53	28.84	129	12224	82400	79649635
Hyponatraemia	162.28	28.84	167	12186	177681	79554354
Hypotension	133.91	28.84	242	12111	440075	79291960
Cardiac arrest	131.22	28.84	147	12206	171949	79560086
Vasoplegia syndrome	131.21	28.84	40	12313	3590	79728445
Lactic acidosis	119.71	28.84	94	12259	70265	79661770
Shock	115.00	28.84	76	12277	43472	79688563
Intentional overdose	114.12	28.84	109	12244	105851	79626184
General physical health deterioration	105.65	28.84	168	12185	275070	79456965
Acute kidney injury	104.90	28.84	241	12112	519163	79212872
Fatigue	93.53	28.84	16	12337	929711	78802324
Septic shock	90.29	28.84	103	12250	122698	79609337
Myasthenia gravis	86.95	28.84	39	12314	10360	79721675
Pulseless electrical activity	84.25	28.84	42	12311	14118	79717917
Acute respiratory distress syndrome	83.96	28.84	63	12290	44004	79688031
Respiratory failure	78.55	28.84	117	12236	180794	79551241
Blood uric acid increased	77.64	28.84	39	12314	13321	79718714
Peripheral ischaemia	77.58	28.84	35	12318	9422	79722613
Off label use	74.56	28.84	307	12046	906908	78825127
Constipation	72.69	28.84	145	12208	282905	79449130
Abdominal pain	66.90	28.84	170	12183	389399	79342636
Intestinal ischaemia	66.32	28.84	35	12318	13235	79718800
Headache	66.19	28.84	11	12342	653761	79078274
Drug ineffective for unapproved indication	65.39	28.84	58	12295	51180	79680855
Arthralgia	64.08	28.84	7	12346	571796	79160239
Electrocardiogram QRS complex prolonged	64.05	28.84	32	12321	10801	79721234
Bradycardia	60.72	28.84	89	12264	135468	79596567
Dizziness	60.13	28.84	6	12347	526435	79205600
Haemodynamic instability	60.09	28.84	36	12317	17346	79714689
Diarrhoea	59.92	28.84	31	12322	880458	78851577
Hyperphosphataemia	56.79	28.84	25	12328	6351	79725684
Renal injury	55.78	28.84	34	12319	16893	79715142
Rash	55.77	28.84	11	12342	578347	79153688
Respiratory depression	51.50	28.84	39	12314	27591	79704444
Pulse absent	51.49	28.84	27	12326	10076	79721959
Hyperdynamic left ventricle	51.17	28.84	12	12341	391	79731644
Malaise	50.07	28.84	8	12345	489861	79242174
Anion gap	49.96	28.84	17	12336	2164	79729871
Serotonin syndrome	49.71	28.84	47	12306	44980	79687055
Pruritus	49.23	28.84	3	12350	394645	79337390
Analgesic therapy	49.09	28.84	14	12339	995	79731040
Dry mouth	48.70	28.84	64	12289	87955	79644080
Local anaesthetic systemic toxicity	48.49	28.84	14	12339	1040	79730995
Condition aggravated	46.09	28.84	176	12177	500948	79231087
Dry gangrene	44.89	28.84	13	12340	976	79731059
Sleep disorder therapy	44.45	28.84	13	12340	1011	79731024
Heparin-induced thrombocytopenia	44.07	28.84	24	12329	9658	79722377
Toxicity to various agents	43.75	28.84	154	12199	421386	79310649
Distributive shock	42.81	28.84	16	12337	2671	79729364
Coagulopathy	42.47	28.84	39	12314	35967	79696068
Disseminated intravascular coagulation	40.68	28.84	38	12315	35804	79696231
Compartment syndrome	39.13	28.84	18	12335	5064	79726971
Circulatory collapse	39.08	28.84	38	12315	37630	79694405
Overdose	38.66	28.84	87	12266	184119	79547916
Fall	38.09	28.84	14	12339	487615	79244420
Ischaemic hepatitis	38.00	28.84	16	12337	3648	79728387
Coma	37.89	28.84	61	12292	100588	79631447
Acidosis	37.06	28.84	28	12325	19734	79712301
Asthenia	36.25	28.84	17	12336	511672	79220363
Back pain	35.94	28.84	3	12350	304177	79427858
Incorrect route of product administration	35.79	28.84	35	12318	34894	79697141
Renal failure	33.67	28.84	87	12266	200881	79531154
Pain in extremity	32.93	28.84	8	12345	364530	79367505
Rhabdomyolysis	31.55	28.84	57	12296	103074	79628961
Ischaemia	31.26	28.84	18	12335	8057	79723978
Weight decreased	29.81	28.84	9	12344	355189	79376846
Dyspnoea	29.54	28.84	55	12298	856970	78875065
Iron deficiency	29.09	28.84	19	12334	10635	79721400

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H01BA01	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES POSTERIOR PITUITARY LOBE HORMONES Vasopressin and analogues
FDA CS	M0022562	Vasopressins
FDA PE	N0000009908	Vasoconstriction
FDA PE	N0000175360	Decreased Diuresis
MeSH PA	D050034	Antidiuretic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D003029	Coagulants
MeSH PA	D006401	Hematologic Agents
MeSH PA	D006490	Hemostatics
MeSH PA	D045283	Natriuretic Agents
MeSH PA	D014662	Vasoconstrictor Agents
CHEBI has role	CHEBI:35554	cardiovascular agent
CHEBI has role	CHEBI:50248	hematologic agents
CHEBI has role	CHEBI:52290	mitogens

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Nocturnal enuresis	indication	8009008
Hereditary factor VIII deficiency disease	indication	28293008	DOID:12134
von Willebrand disorder	indication	128105004	DOID:12531
Partial Central Diabetes Insipidus	indication
Cardiac arrest	off-label use	410429000	DOID:0060319
Uremic Bleeding Tendency	off-label use
Chronic glomerulonephritis	contraindication	20917003
Migraine	contraindication	37796009	DOID:6364
Hypertensive disorder	contraindication	38341003	DOID:10763
Uremia	contraindication	44730006	DOID:4676
Heart failure	contraindication	84114007	DOID:6000
Epilepsy	contraindication	84757009	DOID:1826
Asthma	contraindication	195967001	DOID:2841
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.65	acidic
pKa2	12.19	acidic
pKa3	12.56	acidic
pKa4	12.85	acidic
pKa5	13.19	acidic
pKa6	13.43	acidic
pKa7	13.76	acidic
pKa8	10.75	Basic
pKa9	6.4	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
200UNITS/10ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	Dec. 17, 2016	RX	SOLUTION	INTRAVENOUS	9375478	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	Dec. 17, 2016	RX	SOLUTION	INTRAVENOUS	9687526	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	Dec. 17, 2016	RX	SOLUTION	INTRAVENOUS	9744209	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	Dec. 17, 2016	RX	SOLUTION	INTRAVENOUS	9744239	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	Dec. 17, 2016	RX	SOLUTION	INTRAVENOUS	9937223	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	10010575	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9925233	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9925234	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9962422	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9968649	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9974827	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9981006	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 17, 2014	RX	SOLUTION	INTRAVENOUS	9375478	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 17, 2014	RX	SOLUTION	INTRAVENOUS	9687526	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 17, 2014	RX	SOLUTION	INTRAVENOUS	9744209	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 17, 2014	RX	SOLUTION	INTRAVENOUS	9744239	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	10010575	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9925233	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9925234	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9962422	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9968649	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9974827	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9981006	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 12, 2023	RX	SOLUTION	INTRAVENOUS	10010575	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 12, 2023	RX	SOLUTION	INTRAVENOUS	9925233	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 12, 2023	RX	SOLUTION	INTRAVENOUS	9925234	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 12, 2023	RX	SOLUTION	INTRAVENOUS	9962422	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 12, 2023	RX	SOLUTION	INTRAVENOUS	9968649	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 12, 2023	RX	SOLUTION	INTRAVENOUS	9974827	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 12, 2023	RX	SOLUTION	INTRAVENOUS	9981006	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	10010575	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9925233	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9925234	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9962422	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9968649	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9974827	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9981006	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Vasopressin V1a receptor	GPCR	P37288	V1AR_HUMAN	AGONIST	Ki	9.59	CHEMBL	CHEMBL
Vasopressin V1b receptor	GPCR	P47901	V1BR_HUMAN	AGONIST	Ki	9.31	CHEMBL	CHEMBL
Vasopressin V2 receptor	GPCR	P30518	V2R_HUMAN	AGONIST	Ki	8.92	CHEMBL	CHEMBL
Oxytocin receptor	GPCR	P30559	OXYR_HUMAN		Ki	8.78	CHEMBL
Vasopressin V2 receptor	GPCR		V2R_PIG		IC50	8.48	CHEMBL
Oxytocin receptor	GPCR		OXYR_RAT		Ki	8.93	CHEMBL
Vasopressin V2 receptor	GPCR		V2R_RAT		Ki	9.35	CHEMBL
Vasopressin V2 receptor	GPCR		V2R_BOVIN		Kd	8.82	CHEMBL
Vasopressin V1a receptor	GPCR		V1AR_RAT		Kd	9.19	CHEMBL
Vasopressin V1b receptor	GPCR		V1BR_RAT		Ki	9.54	CHEMBL
Vasopressin V1 receptor	GPCR		V1AR_RAT V1BR_RAT		Kd	9.19	CHEMBL

External reference:

ID	Source
4018654	VUID
N0000179795	NUI
D00101	KEGG_DRUG
4018654	VANDF
C1705480	UMLSCUI
CHEBI:9937	CHEBI
CHEMBL373742	ChEMBL_ID
CHEMBL2108986	ChEMBL_ID
DB00067	DRUGBANK_ID
2168	IUPHAR_LIGAND_ID
C016671	MESH_SUPPLEMENTAL_RECORD_UI
Y4907O6MFD	UNII
1098	RXNORM
3144	MMSL
5667	MMSL
d00398	MMSL
002122	NDDF
002123	NDDF
002126	NDDF
005438	NDDF
005439	NDDF
126192003	SNOMEDCT_US
421078009	SNOMEDCT_US
772208008	SNOMEDCT_US
77671006	SNOMEDCT_US
CHEMBL1201528	ChEMBL_ID
644077	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vasopressin	HUMAN PRESCRIPTION DRUG LABEL	1	0517-1020	INJECTION, SOLUTION	20 [USPU]	INTRAVENOUS	NDA	25 sections
Vasopressin	HUMAN PRESCRIPTION DRUG LABEL	1	0517-1020	INJECTION, SOLUTION	20 [USPU]	INTRAVENOUS	NDA	25 sections
Vasopressin	HUMAN PRESCRIPTION DRUG LABEL	1	0517-1020	INJECTION, SOLUTION	20 [USPU]	INTRAVENOUS	NDA	25 sections
Vasopressin	HUMAN PRESCRIPTION DRUG LABEL	1	0517-1030	INJECTION, SOLUTION	20 [USPU]	INTRAVENOUS	NDA	25 sections
Vasopressin	HUMAN PRESCRIPTION DRUG LABEL	1	0548-9701	INJECTION	20 [USPU]	INTRAVENOUS	ANDA	24 sections
VASOPRESSIN	HUMAN PRESCRIPTION DRUG LABEL	1	42367-570	INJECTION	20 U	PARENTERAL	ANDA	24 sections
VASOPRESSIN	HUMAN PRESCRIPTION DRUG LABEL	1	42367-570	INJECTION	20 U	PARENTERAL	ANDA	24 sections
VASOPRESSIN	HUMAN PRESCRIPTION DRUG LABEL	1	63323-930	INJECTION, SOLUTION	20 [USPU]	INTRAVENOUS	ANDA	25 sections
VASOPRESSIN	HUMAN PRESCRIPTION DRUG LABEL	1	65219-039	INJECTION, SOLUTION	20 [USPU]	INTRAVENOUS	ANDA	25 sections
vasopressin	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1642	INJECTION	20 [USPU]	INTRAVENOUS	ANDA	20 sections
vasopressin	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1642	INJECTION	20 [USPU]	INTRAVENOUS	ANDA	20 sections